A murine B cell lymphoma expressing human HER2/neu undergoes spontaneous tumor regression and elicits antitumor immunity

Manuel L. Penichet, Jay S. Dela Cruz, Pia M. Challita-Eid, Joseph D Rosenblatt, Sherie L. Morrison

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In the present study we describe a novel murine tumor model in which the highly malignant murine B cell lymphoma 38C13 has been transduced with the cDNA encoding human tumor-associated antigen HER2/neu. This new cell line (38C13-HER2/neu) showed stable surface expression but not secretion of human HER2/neu. It also maintained expression of the idiotype (Id) of the surface immunoglobulin of 38C13, which serves as another tumor-associated antigen. Surprisingly, spontaneous tumor regression was observed following s.c. but not i.v. injection of 38C13-HER2/neu cells in immunocompetent syngeneic mice. Regression was more frequently observed with larger tumor cell challenges and was mediated through immunological mechanisms because it was not observed in syngeneic immunodeficient mice. Mice that showed complete tumor regression were immune to challenge with the parental cell line 38C13 and V1, a variant of 38C13 that does not express the Id. Immunity could be transferred with sera, suggesting that an antibody response mediated rejection and immunity. Continuously growing s.c. tumors as well as metastatic tumors obtained after the i.v. injection of 38C13-HER2/neu maintained expression of human HER2/neu, which can serve as a target for active immunotherapy. As spontaneous tumor regression has not been observed in other human murine models expressing human HER2/neu, our results illustrate the enormous differences that can exist among different murine tumors expressing the same antigen. The present model provides a useful tool for the study of the mechanisms of protective immunity to B cell lymphoma and for the evaluation of different therapeutic approaches basedon the stimulation or suppression of the immune response.

Original languageEnglish
Pages (from-to)649-662
Number of pages14
JournalCancer Immunology, Immunotherapy
Volume49
Issue number11
StatePublished - Dec 1 2000
Externally publishedYes

Fingerprint

B-Cell Lymphoma
Immunity
Neoplasms
Neoplasm Antigens
Active Immunotherapy
Cell Line
B-Cell Antigen Receptors
Injections
Antibody Formation
Complementary DNA
Antigens
Serum

Keywords

  • HER2/neu
  • Immunotherapy
  • Lymphoma
  • Tumor model
  • Xenogenization

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Oncology

Cite this

A murine B cell lymphoma expressing human HER2/neu undergoes spontaneous tumor regression and elicits antitumor immunity. / Penichet, Manuel L.; Dela Cruz, Jay S.; Challita-Eid, Pia M.; Rosenblatt, Joseph D; Morrison, Sherie L.

In: Cancer Immunology, Immunotherapy, Vol. 49, No. 11, 01.12.2000, p. 649-662.

Research output: Contribution to journalArticle

Penichet, Manuel L. ; Dela Cruz, Jay S. ; Challita-Eid, Pia M. ; Rosenblatt, Joseph D ; Morrison, Sherie L. / A murine B cell lymphoma expressing human HER2/neu undergoes spontaneous tumor regression and elicits antitumor immunity. In: Cancer Immunology, Immunotherapy. 2000 ; Vol. 49, No. 11. pp. 649-662.
@article{092bf0e2ee6c4de493d8f07d50dab9c8,
title = "A murine B cell lymphoma expressing human HER2/neu undergoes spontaneous tumor regression and elicits antitumor immunity",
abstract = "In the present study we describe a novel murine tumor model in which the highly malignant murine B cell lymphoma 38C13 has been transduced with the cDNA encoding human tumor-associated antigen HER2/neu. This new cell line (38C13-HER2/neu) showed stable surface expression but not secretion of human HER2/neu. It also maintained expression of the idiotype (Id) of the surface immunoglobulin of 38C13, which serves as another tumor-associated antigen. Surprisingly, spontaneous tumor regression was observed following s.c. but not i.v. injection of 38C13-HER2/neu cells in immunocompetent syngeneic mice. Regression was more frequently observed with larger tumor cell challenges and was mediated through immunological mechanisms because it was not observed in syngeneic immunodeficient mice. Mice that showed complete tumor regression were immune to challenge with the parental cell line 38C13 and V1, a variant of 38C13 that does not express the Id. Immunity could be transferred with sera, suggesting that an antibody response mediated rejection and immunity. Continuously growing s.c. tumors as well as metastatic tumors obtained after the i.v. injection of 38C13-HER2/neu maintained expression of human HER2/neu, which can serve as a target for active immunotherapy. As spontaneous tumor regression has not been observed in other human murine models expressing human HER2/neu, our results illustrate the enormous differences that can exist among different murine tumors expressing the same antigen. The present model provides a useful tool for the study of the mechanisms of protective immunity to B cell lymphoma and for the evaluation of different therapeutic approaches basedon the stimulation or suppression of the immune response.",
keywords = "HER2/neu, Immunotherapy, Lymphoma, Tumor model, Xenogenization",
author = "Penichet, {Manuel L.} and {Dela Cruz}, {Jay S.} and Challita-Eid, {Pia M.} and Rosenblatt, {Joseph D} and Morrison, {Sherie L.}",
year = "2000",
month = "12",
day = "1",
language = "English",
volume = "49",
pages = "649--662",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "11",

}

TY - JOUR

T1 - A murine B cell lymphoma expressing human HER2/neu undergoes spontaneous tumor regression and elicits antitumor immunity

AU - Penichet, Manuel L.

AU - Dela Cruz, Jay S.

AU - Challita-Eid, Pia M.

AU - Rosenblatt, Joseph D

AU - Morrison, Sherie L.

PY - 2000/12/1

Y1 - 2000/12/1

N2 - In the present study we describe a novel murine tumor model in which the highly malignant murine B cell lymphoma 38C13 has been transduced with the cDNA encoding human tumor-associated antigen HER2/neu. This new cell line (38C13-HER2/neu) showed stable surface expression but not secretion of human HER2/neu. It also maintained expression of the idiotype (Id) of the surface immunoglobulin of 38C13, which serves as another tumor-associated antigen. Surprisingly, spontaneous tumor regression was observed following s.c. but not i.v. injection of 38C13-HER2/neu cells in immunocompetent syngeneic mice. Regression was more frequently observed with larger tumor cell challenges and was mediated through immunological mechanisms because it was not observed in syngeneic immunodeficient mice. Mice that showed complete tumor regression were immune to challenge with the parental cell line 38C13 and V1, a variant of 38C13 that does not express the Id. Immunity could be transferred with sera, suggesting that an antibody response mediated rejection and immunity. Continuously growing s.c. tumors as well as metastatic tumors obtained after the i.v. injection of 38C13-HER2/neu maintained expression of human HER2/neu, which can serve as a target for active immunotherapy. As spontaneous tumor regression has not been observed in other human murine models expressing human HER2/neu, our results illustrate the enormous differences that can exist among different murine tumors expressing the same antigen. The present model provides a useful tool for the study of the mechanisms of protective immunity to B cell lymphoma and for the evaluation of different therapeutic approaches basedon the stimulation or suppression of the immune response.

AB - In the present study we describe a novel murine tumor model in which the highly malignant murine B cell lymphoma 38C13 has been transduced with the cDNA encoding human tumor-associated antigen HER2/neu. This new cell line (38C13-HER2/neu) showed stable surface expression but not secretion of human HER2/neu. It also maintained expression of the idiotype (Id) of the surface immunoglobulin of 38C13, which serves as another tumor-associated antigen. Surprisingly, spontaneous tumor regression was observed following s.c. but not i.v. injection of 38C13-HER2/neu cells in immunocompetent syngeneic mice. Regression was more frequently observed with larger tumor cell challenges and was mediated through immunological mechanisms because it was not observed in syngeneic immunodeficient mice. Mice that showed complete tumor regression were immune to challenge with the parental cell line 38C13 and V1, a variant of 38C13 that does not express the Id. Immunity could be transferred with sera, suggesting that an antibody response mediated rejection and immunity. Continuously growing s.c. tumors as well as metastatic tumors obtained after the i.v. injection of 38C13-HER2/neu maintained expression of human HER2/neu, which can serve as a target for active immunotherapy. As spontaneous tumor regression has not been observed in other human murine models expressing human HER2/neu, our results illustrate the enormous differences that can exist among different murine tumors expressing the same antigen. The present model provides a useful tool for the study of the mechanisms of protective immunity to B cell lymphoma and for the evaluation of different therapeutic approaches basedon the stimulation or suppression of the immune response.

KW - HER2/neu

KW - Immunotherapy

KW - Lymphoma

KW - Tumor model

KW - Xenogenization

UR - http://www.scopus.com/inward/record.url?scp=0034958898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034958898&partnerID=8YFLogxK

M3 - Article

C2 - 11258791

AN - SCOPUS:0034958898

VL - 49

SP - 649

EP - 662

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 11

ER -